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The Roles of Cholesterol and Its
Metabolites in Normal and Malignant
Hematopoiesis
Hideyuki Oguro*
Cellular Engineering, The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States
Hematopoiesis is sustained throughout life by hematopoietic stem cells (HSCs) that
are capable of self-renewal and differentiation into hematopoietic progenitor cells
(HPCs). There is accumulating evidence that cholesterol homeostasis is an important
factor in the regulation of hematopoiesis. Increased cholesterol levels are known to
promote proliferation and mobilization of HSCs, while hypercholesterolemia is associated
with expansion of myeloid cells in the peripheral blood and links hematopoiesis with
cardiovascular disease. Cholesterol is a precursor to steroid hormones, oxysterols,
and bile acids. Among steroid hormones, 17β-estradiol (E2) induces HSC division and
E2-estrogen receptor α (ERα) signaling causes sexual dimorphism of HSC division
rate. Oxysterols are oxygenated derivatives of cholesterol and key substrates for
bile acid synthesis and are considered to be bioactive lipids, and recent studies
have begun to reveal their important roles in the hematopoietic and immune
systems. 27-Hydroxycholesterol (27HC) acts as an endogenous selective estrogen
receptor modulator and induces ERα-dependent HSC mobilization and extramedullary
hematopoiesis. 7α,25-dihydroxycholesterol (7α,25HC) acts as a ligand for Epstein-Barr
virus-induced gene 2 (EBI2) and directs migration of B cells in the spleen during the
adaptive immune response. Bile acids serve as chemical chaperones and alleviate
endoplasmic reticulum stress in HSCs. Cholesterol metabolism is dysregulated in
hematologic malignancies, and statins, which inhibit de novo cholesterol synthesis, have
cytotoxic effects in malignant hematopoietic cells. In this review, recent advances in our
understanding of the roles of cholesterol and its metabolites as signaling molecules in
the regulation of hematopoiesis and hematologic malignancies are summarized.
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INTRODUCTION
Hematopoietic stem cells (HSCs) sustain blood production throughout life and are the functional
units of bone marrow transplantation. HSCs are capable of self-renewal to maintain their pool
while producing all mature blood cells through differentiation intomultipotent progenitors (MPPs)
and subsequent hematopoietic progenitor cells (HPCs) with limited differentiation potentials
(Figure 1). In adult mice, all HSCs and MPPs fall within the Lineage marker−Sca-1+c-Kit+ (LSK)
fraction (1–3), which is a heterogeneous population that contains a mixture of hematopoietic
stem and progenitor cells (HSPCs), including HSCs, MPPs, and HPCs. HSCs can be further
purified by selecting the CD150+CD48−/low subset (4, 5) or CD34−/lowFlt3− subset (6, 7) of
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FIGURE 1 | Model of the hematopoietic hierarchy. A hierarchical structure of the adult hematopoietic system based on studies by us and others using mice. HSCs
reside at the top of the hierarchy and give rise to MPPs and potentially MEPs. MPPs generate HPCs and MEPs, and HPCs generate GMPs and CLPs. Mature cells
are developed from these oligopotent progenitors, MEPs, GMPs, and CMPs, through intermediate progenitors. Some lineage relationships are under debate.
LSK cells. The HSC population is functionally heterogenous
in terms of cell-cycle kinetics, self-renewal capacity, and
differentiation potential, and the heterogeneity can be
distinguished by additional markers such as CD229 (5) and
von Willebrand factor (8). Human HSPCs can be marked by
Lineage marker−CD38−CD34+ and the HSC population can
be further refined by marking the CD45RA−CD49f+ subset
of Lineage marker−CD38−CD34+ cells (9). HSCs reside in
specialized niches which are local tissue microenvironments
that support HSC behavior and regulate their function, such
as self-renewal, differentiation, and localization, by producing
factors that act directly on HSCs (10). In adults, HSCs are
quiescent and localize primarily in the bone marrow, and their
number is tightly regulated under steady-state conditions,
comprising <0.01% of bone marrow cells in mice. In response to
acute hematopoietic demands such as blood loss, myeloablation,
infection, or pregnancy, HSCs change two aspects of their
steady-state behaviors in order to increase production of
necessary hematopoietic cells (11–14). First, quiescent HSCs
re-enter the cell cycle to proliferate or differentiate through
symmetric or asymmetric cell divisions, and second, they
mobilize from the bone marrow to extramedullary tissues, such
as the spleen, to expand the physical space for hematopoiesis.
In addition to the regulation of HSC behaviors by short-range
factors, such as cytokines, cell-surface proteins, extracellular
matrix components, oxygen tension, and ion levels, that are
generated in their niches, HSCs are also regulated by long-range
systemic signals, such as circulating cytokines, hormones, lipids,
and vitamins. Cholesterol is found in the bloodstream and within
cells, and is an essential structural component of mammalian
plasma membranes and is essential to maintain both membrane
structural integrity and to modulate membrane fluidity (15).
Cholesterol also serves as a precursor for the biosynthesis of
steroid hormones, oxysterols, and bile acids (Figure 2) (16).
These cholesterol metabolites have important biological roles
as signal transducers and chemical chaperones, and there is
accumulating evidence that these metabolites act as systemic
signals that regulate normal and malignant hematopoiesis. This
review discusses recent advances in understanding the roles of
cholesterol and its metabolites in the regulation of hematopoiesis
and hematologic malignancies.
CHOLESTEROL LEVELS AND
HEMATOPOIESIS
In the bloodstream, cholesterol is transported within lipoprotein
particles, which are organized by apolipoproteins that can be
recognized and bound by specific receptors on cell membranes.
There are several types of lipoproteins, such as high-density
lipoprotein (HDL), low-density lipoprotein (LDL), intermediate-
density lipoprotein (IDL), very-low-density lipoprotein (VLDL),
and chylomicrons, in order of higher density to lower density.
LDL is the major cholesterol carrier in the blood and is
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FIGURE 2 | Cholesterol synthetic/metabolic pathways. Pathways of cholesterol biosynthesis (top), bile acid biosynthesis (bottom left), and steroidogenesis (bottom
right) are presented. Enzymes that catalyze the conversions are shown adjacent to the arrows.
recognized by the LDL receptor (LDLR) in peripheral tissues.
LDL is the atherogenic lipoprotein, and increased LDL levels
promote cholesterol accumulation. Macrophages accumulate
oxidized LDL and give rise to foam cells, and contribute to
atherosclerotic plaque formation. HDL opposes this process and
reduces inflammation. HDL is involved in reverse cholesterol
transport, in which HDL serves to shuttle cholesterol from
peripheral tissues to the liver where cholesterol is eventually
converted into bile acids.
Hypercholesterolemia Induces
Proliferation and Mobilization of Mouse
Hematopoietic Stem and Progenitor Cells
Several studies have shown a strong correlation between
plasma cholesterol levels and the mobilized HSC number in
the peripheral blood using mouse models. Gomes et al. showed
that mice fed a high-fat/high-cholesterol (HFHC) diet for 30
days displayed thrombocytosis, lymphocytosis, and an increase
in the number of HSPCs mobilized into the peripheral blood,
while the HSPC number in the bone marrow decreased (17).
They also found that the HFHC diet induced increased plasma
levels of C-X-C motif chemokine ligand 12/ stromal cell-derived
factor 1 (CXCL12/SDF1), a chemokine which is chemotactic
for HSCs that express its receptor C-X-C motif chemokine
receptor 4 (CXCR4) (18). Apolipoprotein E (APOE) is a key
component in cholesterol metabolism and Apoe-deficient mice
cause hypercholesterolemia (19, 20). Apoe-deficient mice fed an
HFHC diet developed monocytosis (21–23), and Murphy et al.
also reported neutrophilia associated with the proliferation and
expansion of HSPCs in the bone marrow (23). Interestingly,
APOE was expressed on the surface of HSPCs and acted cell
autonomously to control HSPC proliferation, monocytosis,
neutrophilia, and monocyte accumulation in atherosclerotic
lesions, as revealed by transplantation of Apoe-deficient bone
marrow cells. LDLR deficiency causes impaired LDL clearance,
resulting in high plasma LDL-cholesterol levels and causing
familial hypercholesterolemia. LDL receptor-deficient (Ldlr−/−)
mice fed an HFHC diet displayed hypercholesterolemia
associated with increased HSPCs in both bone marrow and
peripheral blood, and increased monocytes and granulocytes in
the peripheral blood (24, 25). In addition to their mobilization,
more HSPCs in the bone marrow incorporated the DNA
synthesis marker 5-bromo-2′-deoxyuridine (BrdU) in Ldlr−/−
mice on an HFHC diet as compared to in Ldlr−/− mice on a
normal diet, indicating that hypercholesterolemia promoted
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HSPC proliferation. In contrast, infusion with reconstituted
HDL reduced the frequency and proliferation rate of HSPCs
in the bone marrow, highlighting the opposing effects of LDL
and HDL on HSPC proliferation. Scavenger receptor type
BI (SR-BI, encoded by Scarb1 gene) is a HDL receptor, and
Scarb1−/− mice showed increased plasma total cholesterol levels
with unchanged plasma concentration of apoA-I, the major
protein in HDL (26). Gao et al. reported that Scarb1−/− mice
fed an HFHC diet showed significantly increased the number
of HSPCs in the bone marrow, spleen, and peripheral blood,
as well as the proliferation of HSPCs as compared to wild-type
mice fed an HFHC diet (27). Interestingly, HSPCs in Scarb1−/−
mice fed an HFHC diet displayed increased levels of reactive
oxygen species (ROS). Elevation of ROS levels hinders HSC
quiescence and self-renewal, and accelerates HSC exhaustion
(28). Injection of ROS inhibitor N-acetylcysteine attenuated
HSPC expansion and leukocytosis in Scarb1−/− mice fed an
HFHC diet, suggesting a correlation between ROS levels and
HSPC proliferation. Tie et al. also reported that Apoe-deficiency
increased the number and ROS levels of HSPCs, and these were
further increased by the HFHC diet (29). They also observed
shorter telomere length in HSPCs in Apoe−/− mice as compared
to wild-type mice, suggesting accelerated aging of HSPCs, and
this phenotype was reversed by treating Apoe−/− mice with N-
acetylcysteine. These studies clearly indicate increased systemic
cholesterol levels promote proliferation and mobilization
of HSPCs.
Cholesterol Efflux Pathways Regulate
Proliferation and Mobilization of Mouse
Hematopoietic Stem and Progenitor Cells
ABCA1 and ABCG1, adenosine triphosphate-binding cassette
transporters, play a key role in promoting active cellular
cholesterol efflux (30). Yvan-Charvet et al. reported that
Ldlr−/− mice on an HFHC diet that were transplanted with
Abca1−/−Abcg1−/− bone marrow cells showed accelerated
atherosclerosis and extensive infiltration of myocardium
and spleen with macrophage foam cells as compared to
transplantation with wild-type bone marrow cells (31). The same
group subsequently reported that Abca1−/−Abcg1−/− mice on a
normal diet displayed five-fold increase of HSPCs (including the
CD34+CD150+Flt3− highly-pure HSC population) in the bone
marrow, as well as the increase in the S/G2/M fraction in HSPCs
(32). The overall BrdU incorporation of Abca1−/−Abcg1−/−
bone marrow cells was increased in vitro, whereas when wild-
type bone marrow cells were mixed with Abca1−/−Abcg1−/−
bone marrow cells, the overall BrdU incorporation of wild-type
bone marrow cells was not increased, suggesting that HSPC
proliferation in Abca1−/−Abcg1−/− mice was caused by cell
autonomous effects. Interestingly, in their next report, they
showed that Abca1−/−Abcg1−/− mice also displayed an increase
in HSPCs in the peripheral blood, spleen, and liver, indicating
HSPC mobilization and extramedullary hematopoiesis (33).
In this study, they performed a competitive bone marrow
transplantation experiment by transplanting a mixture of equal
numbers of bone marrow cells from wild-type and Abca1−/−
Abcg1−/− mice into wild-type recipient mice, and found that
HSPC mobilization of both the Abca1−/− Abcg1−/− and
wild-type donor cells was induced, suggesting that there is a
cell-extrinsic factor that induces HSPC mobilization of wild-type
donor cells fromAbca1−/−Abcg1−/− donor cells. Plasma levels of
granulocyte colony-stimulating factor (G-CSF) were significantly
increased in recipients of Abca1−/−Abcg1−/− bone marrow cells
and the mobilization of Abca1−/−Abcg1−/− HSPCs was reduced
by injection of G-CSF-neutralizing antibody. Interleukin-17
(IL-17) is a potent inducer of G-CSF (34), and the production
of IL-17 can be mediated by the secretion of interleukin-23
(IL-23) from splenic phagocytic macrophages and dendritic
cells (35). In the recipients of Abca1−/−Abcg1−/− bone marrow
cells, plasma G-CSF levels and colony-forming HSPC numbers
in the blood were normalized by an IL-17-blocking antibody,
and plasma levels of IL-17 and G-CSF, as well as colony-
forming HSPCs in the blood, were reduced by administration
of IL-23 receptor-neutralizing antibody. Both myeloid cell
(including macrophages) -specific and dendritic-cell specific
deletion of Abca1 and Abcg1 using lysM-cre; Abca1fl/fl; Abcg1fl/fl
mice, and CD11c-cre; Abca1fl/fl; Abcg1fl/fl mice, respectively,
exhibited increased levels of splenic IL-23, plasma IL-17 and
G-CSF, and colony-forming HSPCs in the blood, suggesting
that IL-23/IL-17/G-CSF signaling is associated with enhanced
HSPC mobilization in Abca1−/−Abcg1−/− mice. They further
reported that CXCL12 levels and the number of N-Cadherin+
osteoblasts, one of the CXCL12-expressing cell populations in
the bone marrow (36), were decreased in the bone marrow of
Abca1−/−Abcg1−/− mice, an effect that might be caused by
depletion of bone marrow macrophage populations due to an
enhanced IL-23/IL-17/G-CSF signaling axis. Thus, this study
supports a step-wise mechanism by which increased intracellular
cholesterol levels lead to mobilization of HSCs: (1) increased
cholesterol initially promotes secretion of pro-inflammatory
cytokines from immune cells, (2) this increases production of
G-CSF by bone marrow stromal cells, (3) reducing osteoblast
number and osteoblast production of CXCL12, a chemokine
which attracts HSCs, and (4) leads to HSC mobilization into
the bloodstream. They subsequently reported that Ldlr−/−
recipient mice that received lysM-cre; Abca1fl/fl; Abcg1fl/fl
bone marrow cells and were fed an HFHC diet developed
atherosclerosis associated with monocytosis and neutrophilia
(37). The authors demonstrated a cell-extrinsic mechanism
in which the expression of macrophage colony-stimulating
factor (M-CSF) and G-CSF were increased in the spleen, and
this might cause monocyte and neutrophil production in the
bone marrow.
Cholesterol Levels and
Human Hematopoiesis
Cholesterol homeostasis also affects human hematopoiesis.
Crysandt et al. performed a retrospective analysis of a
variety of clinical parameters in 83 patients following high-
dose cyclophosphamide and G-CSF treatment and found that
patients with hypercholesterolemia showed a substantially higher
number of harvested CD34+ HSPCs in the peripheral blood
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as compared to normocholesterolemic patients (38). 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase is a rate-
limiting enzyme of de novo cholesterol synthesis, and statins,
as inhibitors of HMG-CoA reductase, prevent the conversion of
HMG-CoA to L-mevalonate and inhibit downstream cholesterol
biosynthesis (Figure 2). Cimato et al. treated human subjects
with different statins, atorvastatin, pravastatin, and rosuvastatin,
to vary cholesterol levels and analyzed the number of mobilized
CD34+ HSPCs in the peripheral blood (39). They found a
positive correlation between CD34+ HSPC number and both
total and LDL-cholesterol levels. In addition, G-CSF and its
upstream regulator IL-17 both correlated positively with LDL-
cholesterol levels. Gao et al. studied the correlation between
HDL and white blood cell levels in patients with coronary heart
disease (27). They found negative correlations between HDL
levels and both total white blood cell and neutrophil counts in
the peripheral blood, and patients with low HDL-cholesterol had
more mobilized Lineage−CD34+CD38−CD45RA−/low HSCs in
the peripheral blood as compared to the patients with normal
HDL-cholesterol. Tolani et al. analyzed data from a clinical
trial of rosuvastatin in children with heterozygous familial
hypercholesterolemia and found that the children with the lowest
HDL-cholesterol levels had higher monocyte counts in the
peripheral blood, and there was an inverse correlation between
HDL levels and monocyte percentage (40). Thus, increased
cholesterol levels induce mobilization of not only mouse HSCs
but human HSCs, which suggests that cholesterol level is a
factor that should be considered when mobilizing HSCs for
clinical transplantation.
ROLES OF CHOLESTEROL METABOLITES
IN HEMATOPOIESIS
Sex Steroid Hormones
Estrogens and androgens are classically recognized as sex steroid
hormones, and progestogen are recognized as a third class of
sex steroid hormones. Each of these sex steroid hormones is
synthesized from cholesterol, and the first and rate-limiting step
of the steroidogenic pathway is the cleavage of the cholesterol
side chain by P450scc (CYP11A1) to convert into pregnenolone
(Figure 2) (41). Estrogens are produced in gonadal and extra-
gonadal tissues. In females, 17β-estradiol (E2), a most potent
estrogen, is produced primarily by theca and granulosa cells in
the ovaries. Androstenedione is generated from cholesterol and
is converted into testosterone by aromatase in theca cells, and
they are further converted into E2 by aromatase in granulosa
cells. Testosterone is the primary androgen secreted from Leydig
cells in the testes, and small amounts are also secreted from
theca cells in the ovaries. Progesterone is a critical progestogen
to establish and maintain pregnancy. Progesterone is produced
from cholesterol in the corpus luteum of the ovary during
early pregnancy and the production is sustained by the placenta
in humans and rodents. In addition to their well-recognized
effects on reproductive tissues, the sex steroid hormones are also
being recognized as having broad physiological effects on non-
reproductive tissues, such as nervous, cardiovascular, skeletal,
immune, and hematopoietic systems. It is known that females
and males differ in innate and adaptive immune responses, and
these sex-biased differences in the immune system contribute
to variations in the prevalence of autoimmune diseases and
malignancies, susceptibility to infectious diseases, and responses
to vaccines (42).
Androgens and Lympho-Hematopoiesis
Several studies have shown that androgens negatively regulate
B lymphopoiesis. Castration of male mice leads to spleen
enlargement and expansion of the B-cell population in the bone
marrow and spleen (43–45). This effect is reversed by androgen
replacement with either testosterone or dihydrotestosterone
(DHT) (46). Androgen-resistant “testicular feminization”
mutant male mice also show expansion of B-cell populations
in the bone marrow and spleen (45, 47). In addition to the
regulation of B lymphopoiesis, castrated mice and testicular
feminization male mice also show thymic hypertrophy,
which can be rescued by DHT administration (43, 45, 48–
50). Experiments transplanting wild-type bone marrow
cells into testicular feminization male mice suggest that
androgen receptors expressed by bone marrow stromal cells
or thymic epithelium modulate B-cell development or thymus
size, respectively (50, 51). Velardi et al. showed that one
mechanism by which androgens influence thymopoiesis is
through direct inhibition of the Notch ligand Dll4 in cortical
thymic epithelial cells (52). Immune function progressively
declines with age in mice and humans (53). In male mice,
castration rejuvenates aged bone marrow and thymus, enhances
peripheral T- and B-cell functions, and promotes immune
recovery following chemotherapy-induced immunodepletion
and HSC transplantation (54–62). These studies indicate that
androgens are critical mediators of age-related lymphoid decline.
Castration also enhances the recovery of bone marrow-resident
HSCs after chemotherapy-induced immunodepletion (62).
Khong et al. demonstrated that the number of HSCs marked
by CD34−Flt3−LSK was significantly increased at 7 days after
castration of 9-month-old mice as compared to sham-treated
mice, and the repopulation potential during serial bone marrow
transplantations was enhanced when using these mice as donors
(63). Their gene expression analyses suggest that castration
induces qualitative changes in both HSCs and their bone
marrow environment.
Estrogens and Lympho-Hematopoiesis
B lymphopoiesis in the bone marrow and T lymphopoiesis
in thymus are drastically reduced during pregnancy (64,
65). Ovariectomy stimulates B lymphopoiesis and results in
increased numbers of B cells in the bone marrow (66, 67),
and it is reversed by administration of E2 (68). Genetically
hypogonadal female mice which have a partial deletion of
the hypothalamic gonadotropin-releasing hormone gene have
a secondary deficiency in gonadal steroidogenesis and show
expansion of B cell progenitors. Estrogen replacement with E2
reversed the increased numbers of B cell progenitors in these
hypogonadal mice (69). Exogenous E2 treatment suppresses B
cell development in both male and female mice (68, 70, 71).
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Very early lymphoid precursors marked by Lineage marker−IL-
7Rα+c-KitloTerminal dexynucleotidyl transferase+ in the bone
marrow are selectively depleted by exogenous E2 treatment
(72). Both stromal-dependent and independent pathways of
estrogen action on developing B cells have been postulated. It
is proposed that bone marrow stromal cells expressing estrogen
receptors mediate negative regulatory effects of E2 on early
pre-B development (47, 73). A study of estrogen receptor
α (ERα) male knockout mice by Thurmond et al. indicated
that ERα is necessary for development of normal numbers
of B cells in the bone marrow (74). They investigated the
effect of E2 on lymphopoiesis by performing bone marrow
transplantation using ERα-deficient mice as donors, recipients,
or both, and treated with E2. They demonstrated that exogenous
E2-induced alteration of B cell populations was primarily caused
by a hematopoietic cell-intrinsic mechanism rather than by
their environment.
Estrogens also regulate other hematopoietic lineages.
Administration of a high-dose of estrogen induces anemia in
rodents and dogs, regardless of their sex (75–77). Schroeder
et al. reported that E2 sustained proliferation of erythroid
progenitors from chick bone marrow, but E2 also caused
erythroid differentiation arrest and blocked erythrocyte gene
expression (78). Blobel et al. also showed that E2 added to
the culture also reduced the number of erythroid progenitors
from human bone marrow (79). They demonstrated that
the transcriptional activity of GATA1, an erythroid master
transcription factor that is necessary for full maturation of
erythrocytes, was strongly repressed by direct binding of ER
in an E2-dependent manner in NIH 3T3 and COS cell lines.
The same group subsequently reported that inhibition of
GATA1 activity by ER induced apoptosis in a murine Friend
virus-induced erythroleukemia cell line (80). E2 treatment also
stimulates the megakaryocyte colony formation potential of
CD34+ human cord blood cells in vitro (81). E2 promotes
megakaryocyte polyploidization and maturation via activation of
ERβ accompanied by a significant upregulation of the expression
of GATA1, which is also a key regulator of megakaryocyte
differentiation (82). Differentiation of dendritic cells with
characteristics of Langerhans cells from myeloid progenitors
in culture, as induced by granulocyte-macrophage colony-
stimulating factor (GM-CSF), is promoted by addition of E2 and
inhibited by ER antagonists and ERα-deficiency (83). Interferon
regulatory factor 4 (IRF4), a transcription factor induced by
GM-CSF and critical for Langerhans cell development, is a
target of ERα signaling during this process (84). In contrast,
E2 significantly inhibits Flt3-ligand-induced plasmacytoid
and conventional dendritic-cell differentiation in culture by
decreasing numbers of viable differentiated cells (85). Thus,
the effects of E2 are likely to be dependent on the cytokine
pathways that might be operative in the steady state or during
inflammation and disease.
Estrogens Regulate HSC Division Rate
Estrogens also regulate HSC behavior. In our previous study,
we observed that HSCs divide more often in female mice as
compared to male mice (14). Ovariectomy in females (which
depletes both estrogens and progesterone) significantly reduced
HSC division to male levels, while castration of males has no
effect on HSC division. Conversely, administration of exogenous
E2, but not progesterone or dihydrotestosterone, significantly
increased HSC division in both female and male mice. Because
E2 treatment also increased HSC division in ovariectomized
female mice and castrated male mice, its action is independent
of the gonads. Although HSC division rate was increased in
untreated female mice as compared to male mice and in
E2-treated mice of either sex as compared to vehicle-treated
control mice, we did not observe an increase in absolute HSC
numbers in those untreated female mice or E2-treated mice.
Instead, we observed an increased generation of megakaryocyte-
erythroid progenitors (MEPs) in female mice as compared to
male mice, and increased splenic erythropoiesis in E2-treated
mice of both sexes as compared to vehicle-treated control
mice. Given that increased myeloid progenitors including MEPs
may arise directly from the asymmetric division of HSCs
(Figure 1) (86), our observations raise the possibility that the
increased MEPs in female mice reflects increased asymmetric
division of an HSC to produce one HSC and one MEP in
response to E2. ERα, but not ERβ, is highly expressed by
HSCs. Conditional deletion of Esr1, which encodes ERα, from
hematopoietic cells significantly reduced the HSC division rate
in female mice, but not in male mice. Esr1-deficient HSCs of
both sexes were insensitive to exogenous E2 treatment.Moreover,
E2 treatment of chimeric recipient mice transplanted with
equal numbers of wild-type and Esr1-deficient hematopoietic
cells revealed that E2 significantly induced division of wild-
type HSCs but not Esr1-deficient HSCs in the same recipient
mice, indicating that E2 acts directly on HSCs, rather than
acting indirectly by stimulating secondary signals from other
cells. E2 levels increase in females during pregnancy (87),
when extramedullary hematopoiesis is induced to increase the
production of red blood cells. Notably, pregnant mice exhibit
significantly increasedHSC division rate relative to non-pregnant
female mice, and the deletion of Esr1 in hematopoietic cells
significantly reduced the normal increase in HSC division
during pregnancy (Figure 3). Increased spleen size is observed
during pregnancy in mice and humans (88, 89). In addition
to the increased HSC division rate, we found that pregnant
mice exhibited significantly increased cellularity, erythropoiesis,
myelopoiesis, and HSC number in the spleen, indicating
extramedullary hematopoiesis and HSC mobilization, and these
processes also depend upon ERα function in HSCs. Pregnant
mice also had increased absolute HSC numbers in the bone
marrow, but deletion of Esr1 in hematopoietic cells did not
reverse this phenomenon, suggesting the existence of ERα-
independent factor(s) that increase(s) HSC numbers in pregnant
mice. Nevertheless, ERα signaling is critical for the induction of
HSC division and mobilization to the spleen for the expansion of
splenic erythropoiesis.
Illing et al. also reported the effects of E2 on HSC function
(90). In this study, they treated mice with E2 at a dose of
0.24 mg/kg/day for 30 days, which is a higher dose and longer
treatment than our study at a dose of 0.1 mg/kg/day for 7
days. In this condition, they observed a profound reduction
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FIGURE 3 | E2 and 27HC differentially regulate HSC division and mobilization
during pregnancy. Pregnancy upregulates E2–ERα and 27HC–ERα signaling.
E2–ERα signaling induces HSC division in the bone marrow. 27HC–ERα
signaling induces HSC mobilization into the circulation and spleen, and
augments splenic erythropoiesis.
in bone marrow cellularity by E2 treatment. E2 treatment
caused more HSPCs to enter the S phase. They also observed
an increased frequency of long-term reconstituting HSCs in
E2-treated mice by performing bone marrow transplantation
with a limiting dilution assay. However, donor-derived HSPCs
of the bone marrow of the recipient mice after tertiary
transplantation was decreased in the recipients that received
bone marrow cells from E2-treated mice, suggesting exhaustion
of reconstituting cells during serial transplantation. Deletion
of Esr1 reversed the reduction of bone marrow cellularity
by E2 treatment, however it did not reverse the increased
frequency of long-term reconstituting HSCs by E2 treatment.
Sanchez-Aguilera et al. reported the effect of tamoxifen, a
selective estrogen receptor modulator (SERM), on HSC function
(91). Tamoxifen induced HSC division as well as apoptosis in
MPPs, and these effects are mediated by ERα but not by ERβ.
Tamoxifen treatment significantly reduced MPP number, but
not HSC number, and compromised activation of hematopoiesis
after chemotherapy. They observed increased expression of
Myc in HSCs after tamoxifen treatment, and Myc-deficient
MPPs did not undergo apoptosis upon tamoxifen treatment.
Interestingly, female immunodeficient recipient mice support
reconstitution of the blood system by transplanted human
HSCs more efficiently than male immunodeficient recipient
mice (92, 93). Since female mice have higher E2 levels than
male mice and E2 induces HSC division, it is anticipated
that higher E2 levels in female recipient mice will promote
proliferation and differentiation of transplanted HSCs as
compared to male recipient mice with very low E2 levels.
The molecular mechanisms by which E2 regulates HSCs are
not fully understood. Chapple et al. proposed that HSCs from
mice treated with E2 had increased regenerative capacity after
transplantation or irradiation (94). They demonstrated that
E2–ERα signaling induced expression of Ern1, which encodes
Ire1α, to activate the Ire1α-Xbp1 pathway of the unfolded
protein response, and promoted resistance of HSCs against
proteotoxic stress.
27-Hydroxycholesterol Regulates
HSC Mobilization
Oxysterols are oxygenated derivatives of cholesterol and
key substrates for bile acid synthesis (Figure 2) (16). In
the classic pathway of bile acid synthesis, cholesterol is
converted into 7α-hydroxycholesterol (7αHC) by cholesterol
7α-hydroxylase CYP7A1, a rate limiting step that occurs
in the liver. In alternative pathways that occur primarily
in extrahepatic tissues, cholesterol is converted into 24-
hydroxycholesterol (24HC), 25-hydroxycholesterol (25HC), and
27-hydroxycholesterol (27HC) by cholesterol 24-hydroxylase
CYP46A1, cholesterol 25-hydroxylase CH25H, and sterol 27-
hydroxylase CYP27A1, respectively. Oxysterols are considered
to be bioactive lipids and recent studies have started to
reveal their important roles in both the hematopoietic and
immune systems. 27HC is the most abundant circulating
oxysterol and acts as an endogenous SERM which can
bind to ERs and regulate their function (95). Plasma 27HC
levels strongly correlate with total cholesterol levels (96), as
27HC is generated directly from cholesterol by the sterol
27-hydroxylase CYP27A1. Plasma 27HC levels are greatly
reduced in Cyp27a1-deficient mice (97). CYP27A1 is abundant
in the liver, but it is also expressed in extrahepatic tissues
(16). Dietary or genetic changes that elevate 27HC levels
modulate ER activity, thereby inhibiting vascular repair in
cardiovascular disease (95), promoting ER-positive breast
cancer growth (98, 99), and increasing the severity of
atherosclerosis (100).
We have demonstrated that the increases in HSC division,
HSC mobilization, and extramedullary hematopoiesis during
pregnancy require ERα in HSCs, and E2 treatment induces
HSC division as described above (14). Interestingly, our recent
study revealed that treatment of mice with E2 did not increase
HSC number in the spleen, indicating that E2 treatment does
not induce HSC mobilization (101). In contrast, treatment
with 27HC, another endogenous ER ligand, increased HSC
number in the spleen but not HSC division in the bone
marrow, indicating a role in inducing HSC mobilization. We
demonstrated that the effect of 27HC on HSC mobilization is
nullified by deletion of Esr1 in hematopoietic cells, indicating that
27HC-induced HSC mobilization is dependent on ERα. Plasma
cholesterol levels increase in humans during pregnancy (102).
During pregnancy in mice, we observed significant increases in
27HC levels in HSPCs. Cyp27a1-deficient mice had significantly
reduced HSC mobilization and extramedullary hematopoiesis
during pregnancy, while the increased rate of HSC division in
the bone marrow during pregnancy was not affected. These
findings indicate that 27HC acts in concert with E2 to promote
hematopoiesis during pregnancy by regulating ERα signaling
in HSCs (Figure 3). As described above, increased cholesterol
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levels promote HSC mobilization in mice and humans, and
increased HSC mobilization in Abca1−/−Abcg1−/− mice is
associated with elevated serum G-CSF levels (33). In our study,
we observed that 27HC treatment significantly induced HSC
mobilization in mice deficient for Csf3, which encodes G-
CSF (101). Together, 27HC and G-CSF additively increased
the numbers of colony-forming HSPCs in the peripheral
blood. Therefore, 27HC and G-CSF likely act through distinct
mechanisms to induce HSC mobilization. These findings suggest
an alternative model that the ability of elevated cholesterol
levels to promote HSC mobilization is mediated by increases
in 27HC production, because treating mice with 27HC induces
HSC mobilization and 27HC levels increase as cholesterol
levels increase.
E2, 27HC, and ERα
ERα is a nuclear receptor transcription factor and E2 is the
most potent endogenous estrogen. Different ER ligands are
known to have distinct effects on ERα-mediated regulation
of gene expression, and ER ligands differ in their structures
and their effects on ER conformation (103–106). For example,
Wardell et al. used breast cancer cell lines to test E2 and
five different synthetic ER ligands and observed different gene
expression patterns regulated by different ER–ligand complexes
(106). 27HC induces a unique conformational change in the ER
that is different from that mediated by E2 and other ER ligands
(107). Different ER–ligand complexes also engage functionally
distinct coregulators by selective recruitment of coactivators
and corepressors to activate and repress expression of target
genes, respectively (108). Thus, as different ER ligands can
act through the ERα to differentially regulate gene expression,
this may explain why E2 and 27HC have distinct effects
on HSCs even though both act through ERα (Figure 3). It
will be interesting to explore the nature of the ERα target
genes as well as the mechanism by which ERα function is
differentially regulated by E2 and 27HC, two major endogenous
ER ligands.
Bile Acids
Bile acids are synthesized from cholesterol in the liver
(Figure 2), secreted into the bile, and delivered to the lumen
of the small intestine where they act as emulsifiers of dietary
lipids, cholesterol, and fat-soluble vitamins (16). However,
bile acids have additional roles (109). Tauroursodeoxycholic
acid (TUDCA) serves as a chemical chaperone and reduces
endoplasmic reticulum stress (110). HSCs are predisposed
to apoptosis through misfolded protein accumulation in the
endoplasmic reticulum caused by cellular stress that subsequently
activates the unfolded protein response (111). Addition of
TUDCA to cultured mouse HSCs alleviates endoplasmic
reticulum stress and increases their capacity to reconstitute the
hematopoietic system in recipient mice upon transplantation
(112). In contrast to the quiescent state of adult HSCs in
the bone marrow, HSCs undergo a rapid expansion in the
fetal liver during development (113). Adult HSCs in the bone
marrow have a lower rate of protein synthesis as compared
to most other hematopoietic cells (114). Sigurdsson et al.
reported that although fetal-liver HSCs had a higher rate of
protein synthesis as compared to adult HSCs in the bone
marrow, fetal-liver HSCs had lower expression of endoplasmic
reticulum stress response genes (115). In addition to the role
of CYP27A1 for side chain oxidation of cholesterol for the
generation of 27HC to initiate the alternative acidic bile acid
biosynthetic pathway, CYP27A1 also catalyzes another side chain
oxidation after the ring modification step of both classic and
alternative acidic bile acid synthesis pathways (Figure 2) (16).
Cyp27a1-deficient mice have significantly decreased bile acids
(97). Sigurdsson et al. also reported that fetuses in Cyp27a1-
deficient mothers displayed significantly reduced levels of total
bile acids as wells as secondary bile acids in the fetal liver,
suggesting that maternal bile acids are transferred to the fetus
during pregnancy (115). Interestingly, the livers of Cyp27a1-
deficient fetuses in Cyp27a1-deficient mothers contained a
significantly lower number of long-term reconstituting HSCs, as
assessed by limiting dilution transplantation assay, and these fetal
HSCs showed significantly higher levels of protein aggregation.
These findings imply that bile acids enable fetal-liver HSCs to
have a higher level of protein synthesis without activating a
stress response, allowing expansion of the HSC pool during
fetal development.
25-Hydroxycholesterol
25HC is generated directly from cholesterol by CH25H, and
25HC is further converted into 7α,25-dihydroxycholesterol
(7α,25HC) by the oxysterol 7α-hydroxylase CYP7B1-mediated
hydroxylation (Figure 2) (116). Expression of Ch25h is
upregulated in macrophages and dendritic cells when they
are exposed to various inflammatory mediators (117–120).
25HC augments the production of inflammatory cytokines
in macrophages, and mediates feedback inhibition of
IL1b expression and inflammasome activation in activated
macrophages in the DNA sensor protein absent in melanoma 2
(AIM2)-dependent manner (121–124). 25HC is strongly induced
following viral infection and by interferon, and it inhibits the
replication of a wide range of enveloped viruses (125, 126).
25HC also promotes macrophage foam cell formation (127).
Epstein-Barr virus-induced gene 2 (EBI2), a G protein-coupled
receptor also known as GPR183, controls follicular B-cell
migration and T-cell-dependent antibody production (128, 129).
7α,25HC acts as a ligand for EBI2 and directs migration of B cells
in the spleen during the adaptive immune response (130, 131).
EBI2 and 7α,25HC also regulate splenic CD4+ dendritic cells for
positioning in marginal zone bridging channels to maintain their
homeostasis and mount a response against certain antigens, and
positioning of activated CD4T cells at the interface of the follicle
and T zone to interact with activated dendritic cells (132–134).
Thus, 25HC broadly regulates innate and adaptive immune
cell behavior. The 7α,25HC/EBI2 axis also regulates bone mass
homeostasis (135). EBI2 is expressed in monocyte/osteoclast
precursors, and 7α,25HC is secreted by osteoblasts. EBI2 guides
osteoclast precursors toward bone surfaces by promoting their
movement and positioning, which facilitates fusion of osteoclasts
and enhances the development of large osteoclasts to maintain
bone mass homeostasis.
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CHOLESTEROL SYNTHESIS/METABOLISM
AND HEMATOLOGIC MALIGNANCIES
Cholesterol metabolism is dysregulated in hematologic
malignancies. The rate of cholesterol synthesis is higher in
cells from acute myeloid leukemia (AML) patients as compared
to healthy subjects (136). Hypocholesterolemia is frequently
observed due to elevated LDL uptake by leukemia cells (137–
139), but elevated cholesterol levels in leukemia cells have
also been reported (140–143). Yvan-Charvet et al. reported
that HFHC diet administered Ldlr+/− mice transplanted with
cellular cholesterol efflux pathway-deficient Abca1−/−Abcg1−/−
bone marrow cells displayed a myeloproliferative neoplasm
(MPN)-like phenotype, and expression of an APOA1 transgene
that elevates HDL levels suppressed this phenotype (32).
Thus, changes in intracellular cholesterol levels are associated
with the development and maintenance of hematologic
malignancies. Statins have cytotoxic effects in various types
of malignant hematopoietic cells including AML (144–158),
chronic myeloid leukemia (CML) (153, 159–161), MPNs
(162), acute lymphocytic leukemia (ALL) (163, 164), chronic
lymphocytic leukemia (CLL) (165–167), adult T-cell leukemia
(ATL) (168), lymphoma (169, 170), and multiple myeloma
(171–176). To identify compounds that can inhibit the stem
cell activity of leukemia-initiating cells (LICs), Hartwell et al.
performed a high-throughput screen in a bone marrow-
mimicking culture system in which LICs expressing the
MLL-AF9 fusion oncogene were co-cultured with a bone
marrow stromal cell line (177). Among the compounds that
selectively inhibited LICs but not normal HSPCs, lovastatin
also inhibited LIC stem cell activity in an in vivo bone marrow
transplantation model. Although these reports demonstrate
the effectiveness of statins, the mechanisms of their anticancer
effects are not fully understood. Griner et al. reported that
MPN-associated JAK2V617F localized to lipid rafts, subdomains
of the plasma membrane that contain protein receptors
and a high concentration of cholesterol, and simvastatin
inhibited this localization and JAK2V617F-dependent cell growth
in MPN model cell lines (162). Simvastatin also inhibited
erythroid colony formation of primary cells from MPN
patients, but had no effect on cells from healthy individuals.
Other than the cholesterol-lowering effect, inhibition of the
mevalonate pathway by statins also reduces the levels of
farnesyl pyrophosphate and geranylgeranyl pyrophosphate and
thereby inhibits protein farnesylation and geranylgeranylation,
modifications that are important for a variety of cellular
processes including cell proliferation, survival, and migration
(Figure 2). Thus, the anticancer effects of statins could also
be rendered through changes in these other cellular processes
(157, 158, 170, 176).
Among the metabolites of cholesterol, oxysterols such
as 7βHC, 25HC, 7β,25HC, 7-ketocholestanol, and 7-
ketocholestanol have cytotoxic effects on leukemia and
lymphoma cells (178–183). Tsujioka et al. reported that
DNA methyltransferase inhibitors induced CH25H expression
with enhanced 25HC production and promoted apoptosis in
leukemia and myelodysplastic syndrome (MDS) cell lines, while
exogenous 25HC treatment suppressed cell growth of leukemia
andMDS cell lines (184). Other than oxysterol, Sanchez-Aguilera
et al. reported that tamoxifen treatment blocked development
of JAK2V617F-induced MPN in mice and induced apoptosis of
human MPN cells from patients with JAK2V617F mutation in a
xenograft model (91). They also demonstrated that tamoxifen
treatment reduced leukemic burden in a mouse model of AML
using mice transplanted with bone marrow cells expressing
the MLL-AF9 oncogene. Their findings have uncovered the
potential role of estrogen signaling in leukemia and suggest
the potential use of SERMs as a treatment for leukemia. The
roles of cholesterol metabolites in hematologic malignancies
are not yet fully explored, and further studies of cholesterol
metabolites are expected to elucidate their roles in hematologic
malignancies and their potential in preventing and treating
hematologic malignancies.
CONCLUSION AND FUTURE DIRECTIONS
Cholesterol and its metabolites are now being recognized to have
important roles in broad biological processes by regulating a wide
variety ofmolecularmachinery. Advances in understanding these
molecular mechanisms will benefit human health. One potential
clinical application of molecules that regulate or are regulated
by cholesterol metabolism is to enhance mobilization of HSCs
for transplantation. To enable efficient collection of mobilized
HSCs from the peripheral blood for HSC transplantation, donors
are treated with HSC-mobilizing agents such as G-CSF (185).
However, a significant proportion of donors fail to reach the
minimum HSC collection threshold required for transplantation
using traditional strategies (186). The failure of mobilization
can increase patient morbidity because patients cannot proceed
to transplantation. Thus, advances in mobilization strategies
that could increase the success of HSC collection without
introducing additional side effects are needed to improve patient
outcomes. For example, administration of 27HC enhances the
mobilization of HSPCs by G-CSF (101). Identification of the
genes downstream of 27HC-ERα signaling that mediate HSC
mobilization may contribute to the development of newmethods
that improve the yield of mobilized HSCs for transplantation,
while also offering an explanation for the long-standing
observation that increased cholesterol levels are associated with
increased HSC mobilization in mice and humans.
High blood cholesterol levels are associated with the
development of atherosclerosis. Atherosclerosis is a progressive
disease in which the inside of the artery become thick and stiff
due to the buildup of the atheromatous plaque which consists
of cholesterol, fat and other substances, and restricts blood
flow and causes complications including myocardial infarction,
peripheral artery disease, and stroke. In addition to lipids,
various types of leukocytes also accumulate in the atheromatous
plaque. Hypercholesterolemia causes monocytosis, and these
monocytes give rise to macrophages which eventually turn
into foam cells by ingesting LDL in the plaque, and promotes
plaque growth and inflammation. Other than monocytes,
diverse immune-cell subsets, such as neutrophils, mast cells,
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B and T lymphocytes, are associated with atherosclerosis
[reviewed in (187, 188)]. Oxysterols are formed and accumulate
in the plaque as a result of LDL oxidation due to the
inflammatory response. Although atherosclerotic properties
of oxysterols have been tested, it is still unclear whether
oxysterols have pro- or anti-atherosclerotic properties [reviewed
in (189)]. Estrogens also affect atherogenesis. Despite of
reports that support the atheroprotective effects of estrogens,
it is also controversial whether they have pro- or anti-
atherosclerotic properties [reviewed in (190)]. After myocardial
infarction, monocyte recruitment is increased, and sustained
and accelerated atherosclerosis is observed in a mouse model.
Interestingly, myocardial infarction causes HSPC mobilization
into the spleen and sustains augmented monocytepoiesis,
providing a possibility of novel therapy to mitigate progression of
atherosclerosis (191, 192). Thus, cholesterol and its metabolites
link hematopoiesis with cardiovascular health, and deciphering
this link is critical for developing new targeted therapies.
The molecular mechanisms underlying the regulation
of normal and malignant hematopoiesis by cholesterol
and its metabolites are not yet fully understood. There are
many drugs that target cholesterol synthetic and metabolic
pathways, and further studies are expected to generate
novel strategies for enhancing hematopoiesis, augmenting
hematopoietic recovery after hematopoietic injuries, improving
collection of mobilized HSCs for transplantation, and treating
hematologic malignancies.
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